May 17, 2018

OICR scientist recognized by AACR for early career contributions to prostate cancer research

Dr. Michael Fraser poses for a photo in front of a whiteboard

Dr. Michael Fraser, Director of the Prostate Program in the Computational Biology group at OICR, has been named a 2018 NextGen Star by the American Association for Cancer Research (AACR). Awarded to only eight researchers around the world, AACR’s NextGen Stars program recognizes outstanding early-career scientists who have made significant contributions to cancer research.

Continue reading – OICR scientist recognized by AACR for early career contributions to prostate cancer research

April 19, 2018

Landmark study links tumour evolution to prostate cancer severity

Largest-ever study of its kind uses a tumour’s past to accurately predict its future

Toronto (April 19, 2018) – Findings from Canadian Prostate Cancer Genome Network (CPC-GENE) researchers and their collaborators, published today in Cell, show that the aggressiveness of an individual prostate cancer can be accurately assessed by looking at how that tumour has evolved. This information can be used to determine what type and how much treatment should be given to each patient, or if any is needed at all.

The researchers analyzed the whole genome sequences of 293 localized prostate cancer tumours, linked to clinical outcome data. These were then further analyzed using machine learning, a type of statistical technique, to infer the evolutionary past of a tumour and to estimate its trajectory. They found that those tumours that had evolved to have multiple types of cancer cells, or subclones, were the most aggressive. Fifty-nine per cent of tumours in the study had this genetic diversity, with 61 per cent of those leading to relapse following standard therapy.

Continue reading – Landmark study links tumour evolution to prostate cancer severity

September 29, 2017

OICR 2016/17 Annual Report

OICR Annual Report 2016/17

We are pleased to share the Ontario Institute for Cancer Research (OICR) Annual Report for 2016/17.

We are living in an era of unprecedented innovation in cancer research. Recent advances have helped us to better understand cancer and allowed for collaboration on a scale that was previously not possible. This work is happening now and it is happening right here in Ontario.

Continue reading – OICR 2016/17 Annual Report

September 25, 2017

New study uncovers the role of mitochondrial DNA in prostate cancer

An image of mitochondria

Since mitochondria are inherited maternally, it may strike some as an odd place to go looking for connections to prostate cancer. But recently an international research team explored that relationship by looking at how the small amount of DNA contained in mitochondria, a cellular structure, is involved in prostate cancer.

Continue reading – New study uncovers the role of mitochondrial DNA in prostate cancer

January 10, 2017

New prognostic test for prostate cancer now closer to clinical use

Dr. Emilie Lalonde

Prostate cancer is the most common cancer in Canadian men, but there is still no one-size-fits-all strategy for treating the disease. Currently it is difficult to choose exactly the right type and amount of treatment for each individual because it is hard to accurately assess how aggressive the cancer is. Researchers are now a step closer to bringing a powerful new prognostic tool into clinical use.

Continue reading – New prognostic test for prostate cancer now closer to clinical use

January 9, 2017

Pan-Canadian research team uncovers ‘signature’ to reduce overtreatment of prostate cancer

Dr. Paul Boutros

A team of researchers and clinician-scientists from across Canada have discovered a signature of 41 mutations that are common in prostate cancer and will help to prevent patients with non-aggressive disease from being overtreated. Dr. Paul Boutros, a Principal Investigator in OICR’s Informatics and Bio-computing Program and Co-Lead of the Canadian Prostate Cancer Genome Network (CPC-GENE), answered a few questions about how the signature was developed and its potential impact on patients.

Continue reading – Pan-Canadian research team uncovers ‘signature’ to reduce overtreatment of prostate cancer

January 9, 2017

Scientists identify DNA signature linked to prostate cancer severity

Findings published in renowned journal Nature

January 9, 2017 – TORONTO, ON – The Canadian Prostate Cancer Genome Network (CPC-GENE) has published findings from the world’s most comprehensive genetic analysis of prostate cancer tumours in the journal Nature. Led by Drs. Robert Bristow of the Princess Margaret Cancer Centre and Paul Boutros of the Ontario Institute for Cancer Research, CPC-GENE has uncovered the full set of mutations that can occur in the most common cancer in men. By fully cataloging these mutations, the CPC-GENE team was able to create a new signature that predicts at an early stage whether a prostate cancer tumour will become aggressive or not, allowing for personalized treatment.

Continue reading – Scientists identify DNA signature linked to prostate cancer severity

October 19, 2016

From our Annual Report: Personalizing prostate cancer treatment

Dr. Emilie Lalonde

Prostate cancer is the most common cancer in Canadian men and while it has been the focus of extensive research, an estimated 4,000 Canadians die of the disease each year. That is why six years ago Dr. Paul Boutros and Dr. Rob Bristow set out to sequence the normal and diseased tissue of 350 patients and learn from a clinical perspective how genomic information can be used to guide better treatment.

Continue reading – From our Annual Report: Personalizing prostate cancer treatment

October 12, 2016

OICR’s Natalie Fox awarded Philip Feldberg Studentship by Prostate Cancer Canada

Natalie Fox and supporters

Prostate cancer is a complex disease. In a clinical setting it can be hard for doctors to accurately predict outcomes for prostate cancer patients, especially for those deemed to be at an intermediate risk of recurrence. With intermediate risk cancers, unlike those that are high or low risk, it is unclear how the cancer will develop. This makes it difficult to choose exactly the right therapy and avoid unnecessary treatments and their associated side effects.

Continue reading – OICR’s Natalie Fox awarded Philip Feldberg Studentship by Prostate Cancer Canada

September 15, 2016

Dr. Paul Boutros talks genomics and prostate cancer research

Dr. Paul Boutros, Principal Investigator in Informatics and Bio-computing at OICR, spoke to our partners at Prostate Cancer Canada/Movember Canada about the role of genomics and informatics in prostate cancer research. Boutros also spoke about the CPC-GENE project – the largest study of prostate cancer genomics in the world.

June 28, 2016

Researchers discover protein signatures for accurate non-invasive diagnosis of aggressive prostate cancer

OICR-logoToronto (June 28, 2016) – Researchers at the Ontario Institute for Cancer Research (OICR) and University Health Network (UHN) in Toronto, along with researchers at the Eastern Virginia Medical School, have created protein signatures that accurately diagnose prostate cancer and can distinguish between patients with aggressive versus non-aggressive disease using a simple urine sample. The findings could be developed into a non-invasive “liquid biopsy” that could provide a faster, cheaper and easier method to detect prostate cancer with fewer complications for patients. The findings were published today in the journal Nature Communications.

Continue reading – Researchers discover protein signatures for accurate non-invasive diagnosis of aggressive prostate cancer

January 25, 2016

Discovery by OICR scientists to assist in personalizing prostate cancer treatment

Dr. Paul BoutrosResearchers in OICR’s Informatics and Bio-computing and Genome Technologies Programs, together with their collaborators, have discovered a new sub-type of prostate cancer. The findings, published in the journal Nature Genetics, will assist scientists in creating better diagnostic tests and improve the personalized treatment of prostate cancer. The study was conducted as part of the Canadian Prostate Cancer Genome Network (CPC-GENE), a multidisciplinary team of researchers from across the country that is studying the genetic code of prostate cancer to better predict how patients will respond to treatment. CPC-GENE is part of the Canadian contribution to the International Cancer Genome Consortium.

Continue reading – Discovery by OICR scientists to assist in personalizing prostate cancer treatment

Next Page »